Investigating T Cell Responses in Progressive Multifocal Leukoencephalopathy
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy
This study is trying to see how certain immune cells in people with Progressive Multifocal Leukoencephalopathy (PML) respond to a virus and if this can help us find better treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 4 sites (Bordeaux and 3 other locations) |
| Trial ID | NCT04453917 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the relationship between T cell expression of immune checkpoint molecules and antiviral immune responses in patients with Progressive Multifocal Leukoencephalopathy (PML). It focuses on understanding how these immune checkpoint molecules may influence the control of JC virus replication and the overall outcome of PML. The study will involve collecting blood and urine samples, conducting spinal taps, brain MRIs, and neurological evaluations from 15 patients diagnosed with active PML across four teaching hospitals in the South West of France. The findings could provide insights into potential therapeutic strategies involving immune checkpoint blockade.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with active PML and positive PCR for JC virus in cerebrospinal fluid.
Not a fit: Patients with non-active PML or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic approaches for managing PML by enhancing antiviral immune responses.
How similar studies have performed: While the approach of using immune checkpoint blockade is being explored in other conditions, this specific application in PML is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥18 years old * Informed consent * Active virological PML : Recent neurological symptoms (\< 3 months) with brain MRI lesions suggestive of PML and positive PCR in cerebrospinal fluid for JCV * Affiliated or benefiting from public health insurance. Exclusion Criteria: * Non active PML * Possible PML with negative JCV PCR * Adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision * Pregnant and/or breastfeeding women
Where this trial is running
Bordeaux and 3 other locations
- CHU Bordeaux — Bordeaux, France (Not_yet_recruiting)
- CHU Montpellier — Montpellier, France (Not_yet_recruiting)
- CHU Nimes — Nîmes, France (Not_yet_recruiting)
- CHU de TOULOUSE — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Guillaume MARTIN-BLONDEL — CHU Toulouse
- Study coordinator: Guillaume MARTIN-BLONDEL
- Email: martin-blondel.g@chu-toulouse.fr
- Phone: 5 61 77 96 99
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.